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To the Editor
We agree with Dr Lipworth1 that our study does not address whether treating complex 
sinonasal disease documented by endoscopy would affect asthma outcomes. This was not 
the purpose of our study. The purpose of our study was to determine whether treating 
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chronic sinonasal disease in a diverse patient population in a manner analogous to that 
widely practiced in non–tertiary care specialty practices would improve asthma control.2
Sinonasal disease was determined by using a validated questionnaire with high sensitivity 
and specificity for determining the presence of sinonasal disease, which was superior to 
endoscopy and computed tomographic imaging.3 The reason for using a questionnaire rather 
than invasive testing to document disease was to mirror common clinical practice.
Research personnel were trained in drug administration, and these personnel instructed all 
participants in use of the study drug. Sinus symptoms improved significantly in adults, 
suggesting efficacy of the dose of medication used in this population. Our findings are 
entirely consistent with those of other multicenter studies of nasal steroids in the treatment 
of asthma.4,5
Our overall goal was to study the treatment of sinonasal disease in a diverse patient 
population with poorly controlled asthma to maximize the generalizability of the results to 
clinical practice rather than to test the unified airway disease hypothesis in a highly select 
group of patients.
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